Alliance combines innovative exploratory study design, leading in silico drug development capabilities, and a global licensing network to increase the value of emerging company portfolios and address pipeline gaps for established drug manufacturers.

Diabetes PhysioPD model used to predict long-term clinical outcomes and select doses using only summary pharmacokinetic data from a competitor's short-term Phase I clinical trial

In collaboration with its clients, Lithera, MediciNova, Pfizer, Vitalea, Rosa & Co will present six posters at the 2011 American College on Pharmacometrics in San Diego, CA on April 4, 2011.

In collaboration with Vitalea, Inc., Rosa will present a poster at the 2011 American Society for Clinical Pharmacology and Therapeutics in Dallas, TX entitled "Compartmental Analysis of Urosodiol PK in Neonates using AMS" at 8:00 am on March 4, 2011.